| Glaucoma, Open-Angle
Rhopressa vs Rocklatan
Side-by-side clinical, coverage, and cost comparison for glaucoma, open-angle.Deep comparison between: Rhopressa vs Rocklatan with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsRocklatan has a higher rate of injection site reactions vs Rhopressa based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Rocklatan but not Rhopressa, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Rhopressa
Rocklatan
At A Glance
Ophthalmic (eye drop)
Once daily (evening)
Rho kinase inhibitor
Ophthalmic
Once daily (evening)
Rho kinase inhibitor / prostaglandin F2alpha analogue
Indications
- Glaucoma, Open-Angle
- Ocular Hypertension
- Glaucoma, Open-Angle
- Ocular Hypertension
Dosing
Glaucoma, Open-Angle, Ocular Hypertension One drop in the affected eye(s) once daily in the evening; when used concomitantly with other topical ophthalmic products to lower IOP, administer each product at least 5 minutes apart.
Glaucoma, Open-Angle, Ocular Hypertension One drop in the affected eye(s) once daily in the evening; do not exceed once daily. If used with other topical ophthalmic drugs, administer at least 5 minutes apart.
Contraindications
—
—
Adverse Reactions
Most common (>=20%) Conjunctival hyperemia, corneal verticillata, instillation site pain, conjunctival hemorrhage
Common (5-10%) Instillation site erythema, corneal staining, blurred vision, increased lacrimation, erythema of eyelid, reduced visual acuity
Postmarketing Epithelial corneal edema in patients with pre-existing corneal stromal edema or following ocular procedures affecting corneal endothelial function
Most common (>=11%) Conjunctival hyperemia, instillation site pain, corneal verticillata, conjunctival hemorrhage
Postmarketing Epithelial corneal edema in patients with pre-existing corneal stromal edema or ocular procedures affecting corneal endothelial function
Pharmacology
Netarsudil is a rho kinase inhibitor believed to reduce intraocular pressure by increasing the outflow of aqueous humor through the trabecular meshwork; the exact mechanism is unknown.
Fixed-dose combination of netarsudil (Rho kinase inhibitor) and latanoprost (prostaglandin F2alpha analogue) that reduces elevated intraocular pressure by increasing the outflow of aqueous humor.
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Rhopressa
- Covered on 5 commercial plans
- PA (5/12) · Step Therapy (6/12) · Qty limit (9/12)
Rocklatan
- Covered on 5 commercial plans
- PA (5/12) · Step Therapy (6/12) · Qty limit (9/12)
UnitedHealthcare
Rhopressa
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (2/8) · Qty limit (4/8)
Rocklatan
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (2/8) · Qty limit (4/8)
Humana
Rhopressa
- Covered on 0 commercial plans
- PA (1/3) · Step Therapy (2/3) · Qty limit (1/3)
Rocklatan
- Covered on 0 commercial plans
- PA (1/3) · Step Therapy (2/3) · Qty limit (1/3)
Coverage data sourced from MMIT. Updated monthly.
Savings
No savings programs available for Rhopressa.
No savings programs available for Rocklatan.
Compare Other Drugs
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
RhopressaView full Rhopressa profile
RocklatanView full Rocklatan profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.